Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation
The provided content is empty, so a summary cannot be generated.
RCUS: Future Upside Will Be Anchored By Renal Cancer Trial Progress
Analyst sentiment for Arcus Biosciences (RCUS) is improving, with price targets rising due to strong trial data for casdatifan, a key oncology pipeline asset. While bullish analysts highlight casdatifan's potential in renal cell carcinoma and the broader oncology pipeline, cautious views point to balanced risk-reward and the need for clear near-term catalysts. The company recently filed for a $200m equity offering and announced updated positive data for casdatifan, with multiple readouts planned for 2026.
RCUS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Arcus Biosciences Inc.'s (RCUS) financial performance, highlighting its revenue streams, profitability margins, and competitive standing. The company generates most of its revenue from license and development services, with a 100% gross margin but negative operating and net margins. RCUS is compared to competitors MESO and TWST, showcasing its higher gross margin within the Biotechnology & Medical Research industry.
RCUS Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Arcus Biosciences Inc (RCUS), indicating a "Strong Buy" overall consensus based on 14 technical signals. Key metrics like MACD and moving averages suggest a buy, while RSI is neutral. The report also outlines critical support and resistance levels for the stock.
Arcus Biosciences (NYSE:RCUS) Trading 5.4% Higher Following Analyst Upgrade
Arcus Biosciences (NYSE:RCUS) saw its shares jump 5.4% following an analyst upgrade from Wedbush, which raised its price target from $37 to $41. The company also reported strong Q4 results, beating EPS and revenue estimates. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating, and insider selling by President Juan C. Jaen was noted despite the overall positive momentum.
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00
Wedbush has increased its price target for Arcus Biosciences (NYSE:RCUS) from $37 to $41, maintaining an "outperform" rating, which suggests an 87% upside. This adjustment follows Arcus Biosciences beating quarterly revenue and EPS estimates, though the company remains unprofitable with negative margins. Analysts' consensus rates RCUS as a "Moderate Buy" with an average price target of $30.80.
Behavioral Patterns of RCUS and Institutional Flows
This article analyzes Arcus Biosciences Inc. (NASDAQ: RCUS) using AI models to provide insights into its behavioral patterns and institutional flows. It highlights a positive near-term sentiment while noting a mid-term weak bias within a long-term strong context. The analysis includes specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop loss points, along with multi-timeframe signal analysis.
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound
Arcus Biosciences (RCUS) is currently trading at US$20.28, which is considered undervalued compared to its fair value estimate of $32.30, driven by projections of revenue expansion and margin improvement related to its late-stage HIF-2 alpha inhibitor, casdatifan. Despite a recent short-term decline, the stock has shown a strong one-year return of 148.23%. Investors are advised to consider potential risks such as trial disappointments or regulatory delays that could impact this bullish outlook.
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound
Arcus Biosciences (RCUS) stock has seen mixed performance recently, with short-term declines but a strong 148.23% rebound over the past year. Despite a current trading price of US$20.28, analysts suggest a target of US$33.80 and fair value is estimated at US$32.30, indicating a potential undervaluation, largely due to optimistic projections for its HIF-2 alpha inhibitor, casdatifan. However, investors are cautioned to consider risks like trial disappointments or regulatory delays.
RCUS Price History for Arcus Biosciences Stock
This Barchart.com article provides an extensive price history for Arcus Biosciences Inc (RCUS) stock, including 52-week highs and lows, Fibonacci levels, and the frequency of new highs and lows across various timeframes. It details how Barchart Premier members can access comprehensive historical data, including intraday, daily, weekly, monthly, or quarterly information going back to 1980. The article also explains the various features available on the price history page, such as daily prices, latest trades, corporate actions, and customizable views.
Arcus Biosciences (RCUS) Vanguard shows 0 shares after Jan 12, 2026 realignment
The Vanguard Group has filed an amended Schedule 13G/A, reporting that it now holds 0 shares of Arcus Biosciences (RCUS) common stock, representing 0% of the class. This change is attributed to an internal realignment within Vanguard on January 12, 2026, which led to certain subsidiaries reporting beneficial ownership separately. The filing clarifies that this reflects a change in reporting structure rather than a sale or market transaction.
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Brokerages
Arcus Biosciences (NYSE:RCUS) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average one-year price target of $30.20. Despite recent insider selling and a negative net margin, the company beat its latest quarterly earnings and revenue estimates. Analysts forecast an EPS of -3.15 for the current fiscal year.
Arcus Executives Offload Shares Amid Surge in Hiring—A "Pump and Dump" Warning Sign for RCUS
Arcus Biosciences executives are selling significant portions of their holdings while the company issues equity grants to new hires, raising concerns about a potential "pump and dump" scenario. This insider selling contrasts with high institutional ownership, which is largely passive, and indicates a divergence in confidence regarding the company's near-term prospects. Upcoming clinical milestones and an earnings report on May 5, 2026, will be crucial in determining the future trajectory and validating current valuations of Arcus Biosciences (RCUS).
Two new hires get Arcus stock awards priced at $21.41 a share
Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted equity awards to two new employees. These awards include options to purchase 7,050 shares of common stock at an exercise price of $21.41 per share and restricted stock units for 3,550 shares. The grants were made under the company's 2020 Inducement Plan, adhering to the "inducement exception" of NYSE's Rule 303A.08.
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30
Arcus Biosciences announced that its Chief Operating Officer, Jennifer Jarrett, will resign effective March 30. Her resignation is not due to disagreements with the company, and she will provide advisory services until June 30 under a separation agreement. The company's stock closed down 3.5% following the announcement, although it has shown a 142% return over the past year.
Arcus Biosciences Announces COO Resignation and Transition Plan
Arcus Biosciences (RCUS) announced that its Chief Operating Officer, Jennifer Jarrett, will resign on March 30, 2026. She will provide advisory services until June 30, 2026, and receive an extended period to exercise her vested stock options. The resignation is not due to any disagreement with company operations, indicating an orderly leadership transition.
Arcus Biosciences' Jennifer Jarrett to Resign as COO, Effective March 30, 2026
Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences (RCUS), will resign from her position effective March 30, 2026. She will continue to provide advisory services until June 30, 2026, under a separation agreement. Her resignation is not due to any disagreement with the company regarding its operations, policies, or practices.
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30
Jennifer Jarrett, the chief operating officer of Arcus Biosciences, is resigning effective March 30, a move the company states is not due to disagreements with its operations. Jarrett will provide advisory services until June 30 and her stock option exercise period will be extended. This announcement comes after the company reported mixed Q4 2025 financial results, with EPS beating forecasts but revenue falling short.
Arcus Biosciences COO Jennifer Jarrett to resign March 30
Arcus Biosciences announced that its Chief Operating Officer, Jennifer Jarrett, will resign effective March 30, 2026. Her resignation is not due to any disagreement with the company's operations. Jarrett will provide advisory services until June 30, 2026, and her post-termination option exercise period will be extended to 12 months.
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor
Arcus Biosciences announced that COO Jennifer Jarrett will resign effective March 30, 2026, but will remain as an advisor until June 30, 2026. The company stated her resignation is not due to disagreements, and she will receive an extended period to exercise vested stock options. The full separation agreement will be detailed in Arcus's next quarterly Form 10-Q filing.
Arcus Biosciences, Inc. Announces Resignation of Jennifer Jarrett as Chief Operating Officer, Effective March 30, 2026
Arcus Biosciences, Inc. announced that Jennifer Jarrett has resigned from her position as Chief Operating Officer, effective March 30, 2026. Ms. Jarrett will provide advisory services through June 30, 2026, as part of a separation agreement that includes a standard release of claims.
Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS
Hudson Bay Capital Management LP significantly reduced its stake in Arcus Biosciences, Inc. by 20.9% in the third quarter, now holding 340,000 shares valued at $4.62 million. Despite this, other institutional investors increased their holdings. Arcus Biosciences reported an EPS beat and higher-than-expected revenue but remains unprofitable, with analysts offering a mixed but generally positive outlook on the stock.
RCUS PE Ratio & Valuation, Is RCUS Overvalued
Arcus Biosciences Inc (RCUS) is currently considered undervalued based on its forward P/S ratio of 26.43 compared to its five-year average. The fair price is estimated between $26.03 and $34.67, suggesting an undervaluation of 16.88% from its current price of $21.64. While its P/B ratio is significantly higher than its 3 and 5-year averages, its current P/S ratio, though above the industry average, is deemed sustainable due to robust revenue growth.
(RCUS) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis for Arcus Biosciences Inc. (NASDAQ: RCUS), highlighting a mid-channel oscillation pattern and a strong risk-reward setup targeting an 18.1% gain. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks. The analysis suggests prevailing positive sentiment with specified entry, target, and stop-loss levels for each strategy.
Arcus Biosciences, Inc. (RCUS) Stock Price Today | Live Chart & News
This article provides current stock information for Arcus Biosciences, Inc. (RCUS), including its live price, daily and weekly ranges, market capitalization, and various financial statistics. It also features short-term and long-term price predictions from analysts, detailing expected price movements over different periods. The piece highlights recent performance metrics and offers fundamental data like revenue, net income, and debt-to-equity ratio, alongside a section for recent news and editor's picks.
Arcus Biosciences, Inc. (RCUS) Stock Price History & Data
This article provides historical stock price data and performance metrics for Arcus Biosciences, Inc. (RCUS). It includes information on the stock's 52-week high and low, year-to-date performance, and annual return and market capitalization data from 2018 to 2026. The piece also features recent financial news and editor picks.
Arcus Biosciences, Inc. (RCUS) Stock Price Prediction for 2026, 2030-2040
This article provides stock price predictions for Arcus Biosciences, Inc. (RCUS) for 2026, 2030, and 2040, including monthly forecasts for 2026 and 2027, and year-end projections up to 2040. It also details market capitalization history, analyst consensus ratings, and earnings per share and revenue forecasts. The forecasts are based on a multi-layered methodology that aggregates estimates from leading global investment institutions and market analysts.
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC
Decheng Capital LLC significantly increased its stake in Arcus Biosciences, Inc. ($RCUS) by 242.3% in the third quarter, acquiring an additional 387,609 shares. Other institutional investors like AQR Capital Management LLC, Millennium Management LLC, and Goldman Sachs Group Inc. also boosted their holdings. The report details company financials, analyst ratings, and recent insider selling activities.
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS
WINTON GROUP Ltd has acquired a new position of 92,229 shares in Arcus Biosciences, valued at approximately $1.254 million, making them owners of about 0.09% of the company. Institutional investors hold 92.89% of RCUS, while insiders have recently sold shares worth about $3.97 million. Arcus Biosciences has a market cap of $3.07 billion, recently beat EPS and revenue estimates, and has an average analyst rating of "Moderate Buy" with a target price of $30.20.
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion
Arcus Biosciences (RCUS) saw a 9.5% stock increase following the release of new clinical data for its HIF-2α inhibitor casdatifan, which demonstrated a 45% response rate and 15.1 month median PFS in late-line kidney cancer. The company also announced plans to expand its pipeline into inflammatory and autoimmune diseases. While the new data re-affirms casdatifan as a key near-term catalyst, investors should be aware of widening losses and ongoing shareholder dilution in the context of the company's dependency on external funding.
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings
Arcus Biosciences (RCUS) has seen renewed investor interest following updated clinical data for its kidney cancer drug, casdatifan, a broader pipeline update, and its full-year 2025 earnings. Despite recent short-term share price dips, the stock shows strong long-term momentum with a 134.96% return over the past year. Analysts assess RCUS as undervalued, with an intrinsic value estimate pointing to a significant discount and a fair value of $32.30.
How (RCUS) Movements Inform Risk Allocation Models
This article analyzes Arcus Biosciences Inc. (NASDAQ: RCUS) using AI models to provide trading strategies. It highlights weak near-term sentiment but strong mid and long-term outlooks, presenting specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and key resistance and support levels.
New Arcus Biosciences hires receive stock options at $23.43
Arcus Biosciences, Inc. (NYSE: RCUS) announced the grant of stock options and restricted stock units to two new employees. These equity awards, totaling 17,050 stock options at an exercise price of $23.43 per share and 8,550 restricted stock units, were issued under the Company’s 2020 Inducement Plan. This action is in accordance with the inducement exception under NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings
Arcus Biosciences (RCUS) has garnered investor attention following new clinical data for its kidney cancer drug, casdatifan, a broader pipeline update, and its full-year 2025 earnings report. Despite a recent short-term share price dip, the stock exhibits strong long-term momentum with a 1-year total shareholder return of 134.96%. The company's valuation is discussed, with a fair value estimate suggesting it is undervalued, but this hinges on successful regulatory outcomes and market adoption of casdatifan.
Arcus Biosciences Casdatifan Data Reshapes Kidney Cancer And Valuation Story
Arcus Biosciences (NYSE:RCUS) has released new clinical data for its CD73 inhibitor casdatifan in late-line kidney cancer, showing strong efficacy and a clear link between biomarker suppression and clinical outcomes. The company also announced plans for two new inflammation programs. This data adds significant context to Arcus's stock performance, with shares up 13.7% in the past week and 121.7% over the past year, although the company remains unprofitable.
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45
Citigroup has raised its price target for Arcus Biosciences (RCUS) to $45, while maintaining a "Buy" rating. This update comes amidst various analyst ratings, with other firms also adjusting their price targets, reflecting differing perspectives on the biopharmaceutical company despite a GuruFocus estimated downside.
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00
Citigroup has raised its price target for Arcus Biosciences (NYSE:RCUS) to $45.00 from $44.00, maintaining a "buy" rating and indicating a potential upside of over 100%. This comes after Arcus Biosciences surpassed revenue and EPS estimates in its latest quarter, though it remains unprofitable. The stock is currently rated a "Moderate Buy" by analysts, with significant institutional investment increases despite insider share sales.
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift
Arcus Biosciences (RCUS) saw a 27.0% increase following the release of updated clinical data for its HIF-2α inhibitor casdatifan in kidney cancer, which showed improved progression-free survival and response rates. This data supports a shift towards tyrosine kinase inhibitor-free frontline treatment regimens and reinforces the company's plan to initiate a Phase 3 trial by the end of 2026. Despite continued net losses and rising R&D, analysts project significant revenue growth and a substantial increase in earnings for Arcus Biosciences by 2028.
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift
Arcus Biosciences shares surged 27.0% after the company updated clinical data for its HIF-2α inhibitor casdatifan, which showed promising results in kidney cancer with prolonged progression-free survival and higher response rates. This data supports a shift towards TKI-free frontline treatment regimens for metastatic kidney cancer, with Arcus planning a Phase 3 trial by late 2026. Despite widening net losses and ongoing funding needs, the strong casdatifan data and planned pivotal trials are key catalysts for future investment.
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts
Five analysts have recently evaluated Arcus Biosciences (NYSE: RCUS), resulting in an average 12-month price target of $27.0, an increase from $25.80. Despite challenges in market capitalization and revenue growth, the company demonstrates strong profitability with a net margin of -519.23% and a sound financial structure with a low debt-to-equity ratio. Analysts assess factors like market conditions and company performance, providing ratings and price targets that help investors make informed decisions.
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives
Arcus Biosciences (RCUS) reported a US$106 million Q4 loss and US$33 million in revenue for FY 2025, continuing a trend of negative earnings despite top-line contributions. The company's trailing 12-month net loss reached US$353 million, significantly exceeding its US$247 million revenue base, raising concerns about profitability. While bears highlight increasing losses and no near-term profitability, bulls point to a robust pipeline of 16 products in various clinical phases and a P/S ratio below the broader industry average as indicators of future potential.
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
Arcus Biosciences, Inc. (RCUS) released its 2025 Q4 earnings call presentation, reporting an EPS of -$0.89, which beat estimates by $0.18, and revenue of $33.00M, beating estimates by $8.06M despite an 8.33% year-over-year decrease. The slide deck was published in conjunction with their earnings call, reflecting the company's financial performance.
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives
Arcus Biosciences (RCUS) reported a US$106 million Q4 loss for FY 2025, alongside US$33 million in revenue and a basic EPS loss of US$0.89. The company's trailing 12-month net loss reached US$353 million against US$247 million in revenue, leading to bearish concerns about sustained clinical spending and lack of near-term profitability. Despite significant losses, bullish investors highlight a broad pipeline of up to 16 products in Phase I, 7 in Phase II, and 5 in Phase III as justification for the current investment in growth potential.
FY2030 Earnings Estimate for RCUS Issued By HC Wainwright
HC Wainwright has issued a "Buy" rating for Arcus Biosciences (NYSE: RCUS) with a $32 price target, forecasting a FY2030 EPS of $0.30, significantly above the current consensus estimate of ($3.15). The company recently reported better-than-expected quarterly earnings, though it remains unprofitable. Several other analysts have also updated their ratings and price targets for Arcus Biosciences.
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals
Arcus Biosciences (RCUS) has seen a 99.9% gain over the last year, with its stock currently trading at US$20.27. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued at US$131.16 per share, while a Price-to-Sales (P/S) ratio analysis indicates it is overvalued compared to Simply Wall St's "Fair Ratio" of 0.96x. The article presents "Bull Case" and "Bear Case" narratives for RCUS, with fair values of US$32.30 and US$20.00 respectively, highlighting the mixed signals regarding its current pricing.
Cancer and immune drug developer Arcus Biosciences offers March webcast
Arcus Biosciences (NYSE: RCUS) announced its participation in two upcoming investor conferences in March: the Leerink Global Healthcare Conference and the Barclays 28th Annual Global Healthcare Conference. The company's management team will hold a fireside chat and one-on-one meetings, with a live webcast of the fireside chat available on their website. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory/autoimmune diseases.
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals
This article analyzes Arcus Biosciences (RCUS) valuation following a significant 1-year surge. It uses Discounted Cash Flow (DCF) analysis, which suggests the stock is 84.5% undervalued, and Price vs. Sales (P/S) ratio, which indicates it's overvalued compared to its tailored Fair Ratio. The article also presents Bull and Bear case narratives, illustrating diverse perspectives on the company's future value based on pipeline success and partnership risks.
Arcus Biosciences, Inc. SEC 10-K Report
Arcus Biosciences, Inc. has released its annual Form 10-K report, detailing a net loss of $(353) million, primarily due to increased R&D expenditures. The company, focused on cancer and inflammatory diseases, is advancing several compounds into Phase 3 trials and is engaged in significant collaborations with Gilead and Taiho. Despite facing competition and regulatory hurdles, Arcus aims to leverage strategic partnerships and manage capital effectively to fund operations until at least the second half of 2028.
Late-line kidney cancer patients top a year without progression on Arcus drug
Arcus Biosciences announced new data for its HIF-2a inhibitor, casdatifan, showing a median progression-free survival of 15.1 months and a 45% confirmed overall response rate in late-line metastatic clear cell renal cell carcinoma patients. This data, which will be presented at the ASCO Genitourinary Cancer Symposium, positions casdatifan with best-in-class potential compared to the only currently marketed HIF-2a inhibitor and demonstrates a manageable safety profile. The company highlights the correlation between casdatifan's suppression of serum erythropoietin and clinical benefit, suggesting a promising new treatment option for ccRCC.
Arcus Biosciences’ cancer drug gets orphan drug status
Arcus Biosciences has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its experimental cancer drug, AB521. This designation is for the treatment of pancreatic cancer, a disease with high unmet medical needs. The orphan drug status provides incentives and potential market exclusivity for drugs developed to treat rare diseases.
